October 1, 2024

Supplementary Figure S5 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

View Full Paper

Ask AI

Bookmark

Abstract

Supplementary Figure S5 shows levels of KRAS-MAPK pathway modulation associated with coadministration of MRTX0902 and adagrasib in the murine CT26 (KRAS G12C-mutant) model.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sudhakar et al. (2024) studied this question.

synapsesocial.com/papers/68e56226e2b3180350efee1b https://doi.org/10.1158/1535-7163.27142587

View Full Paper

Ask AI

Bookmark

Abstract

Supplementary Figure S5 shows levels of KRAS-MAPK pathway modulation associated with coadministration of MRTX0902 and adagrasib in the murine CT26 (KRAS G12C-mutant) model.

Supplementary Figure S5 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Abstract

Discussion

Cite This Study

Supplementary Figure S5 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Abstract

Discussion

Cite This Study

Keep reading

Keep reading